Nesina, indicated to improve
glycaemic control in adults with
type 2 diabetes, when added to
other anti-diabetic medications,
will become the first and only
DPP-4 inhibitor to be reimbursed
second line without the need to
demonstrate contraindication or
intolerance to sulphonylurea or
metformin (PD Fri).
This PBS reimbursement for
Nesina will take effect from 1st
December 2013 onwards.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Nov 13
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.